CA-PSMF
3.5.2022 14:02:31 CEST | Business Wire | Press release
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient deaths by 2030, announced the winners of its 2021 Humanitarian and Lewis Blackman awards at its 8th annual World Patient Safety, Science & Technology Summit (WPSSTS). President Bill Clinton, the 42nd President of the United States, was recognized with the Joe Kiani Humanitarian award, Javier Davila received the Beau Biden Humanitarian award and Jannicke Mellin-Olson was honored with the Steven Moreau Humanitarian award. The 2nd annual Lewis Blackman award was presented to Ingrid Bonilla.
“Achieving our mission of zero preventable patient deaths by 2030 relies on individuals coming together to create change,” said Michael Ramsay, MD, CEO of Patient Safety Movement Foundation. “We are proud to recognize all four of this year’s winners for their individual efforts, leadership and commitment to improving patient safety globally.”
The Humanitarian Awards recognize leaders who have made significant progress in the last year eliminating or raising awareness of preventable patient deaths. This year, recipients were honored across three categories – the Joe Kiani award, Beau Biden award and Steven Moreau award. The Joe Kiani award was named after the founder of the Patient Safety Movement Foundation and recognizes individuals who are committed to the foundation’s mission. The Beau Biden award was created in 2018 to honor Beau Biden, former attorney general of Delaware, member of the Army National Guard and late son of President Joe Biden, for his devotion to public service and the safety of others, especially children. The Steven Moreau award is presented annually to a hospital administrator who possesses a zeal for improving patient safety at their hospital. This year’s recipients included:
- President Bill Clinton , 42nd President of the United States, has been a long-standing supporter of patient safety. During his time in office, he was committed to expanding access to affordable, quality health care for all Americans. He received the first-ever Joe Kiani award for his continued support of the Patient Safety Movement Foundation and its goal to reach zero preventable medical deaths by 2030.
- Javier Davila , PSMF ambassador in Mexico, former medical director at the Mexican Social Security Institute and head of medical education, research and health public policy, was recognized with the Beau Biden award for his passion for public service and improving patient safety for others. Since joining PSMF, he has focused on promoting the culture of safety in Mexico and has helped build affiliations with many prestigious public and private hospitals, as well as establish relationships with numerous organizations to help further the mission.
- Jannicke Mellin-Olson , MD, DPH, has been a longtime patient safety advocate. Her passion for patient safety started during her residency at Trondheim University Hospital in Norway, where she worked on a number of patient safety initiatives. She received the Steven Moreau award for her continued efforts to spread the mission to stakeholders across Europe, as well as in her current clinical post at Baerum Hospital in Oslo, Norway.
The Lewis Blackman Leadership Award was established in 2020 to recognize active students or residents pursuing a career in healthcare who demonstrate exemplary leadership skills in patient safety that contribute to PSMF’s vision of eliminating preventable medical harm. It was designed in honor of Lewis Blackman, who died on November 6, 2000 at the age of 15, as a result of preventable medical harm in a healthcare setting with a poor culture of safety and inadequate training. Before his death, he was an outstanding student and his mother, Helen Haskell, has become an advocate for improving patient safety, especially through education.
- Ingrid Bonilla , fourth year medical student at Medical University of South Carolina, has demonstrated an early commitment and passion for improving patient safety. During her time in medical school, she has worked with noted patient safety champions in South Carolina on new criteria to prevent central line infections, collected data on COVID-19 to determine how it presents itself in children and how they should be treated and has also focused on improving communication between patients, families and providers.
The Patient Safety Movement Foundation launched the Humanitarian Awards in 2013 to recognize individuals whose work helps advance patient safety and the Lewis Blackman Award was created in 2019. To learn more about the awards and past winners, visit: https://patient.sm/LewisBlackman .
The full WPSSTS event is available to watch on demand for $20 through May 9, 2022 at: http://patient.sm/summit2022 or free after May 9 at: http://patient.sm/summitYT .
About the Patient Safety Movement Foundation: The Patient Safety Movement Foundation (PSMF), a global non-profit organization founded in 2012, is celebrating 10 years of bringing awareness and creating action to eliminate preventable medical errors. Some estimates predict that one in 12 patients are impacted by a preventable medical error, but that number could be even higher as there is no central database tracking these figures in most countries, including the U.S. Over the last decade, there had been major strides to improve patient safety, but the COVID-19 pandemic stressed the system and it proved not to be resilient and took a step backwards. PSMF has a vision to eliminate preventable patient harm and death across the globe by 2030 – and that starts with raising awareness of this critical issue. It unites patients, advocates, health workers, medical technology companies, government, employers and private payers in support of this cause. From its evidence-based best practice solutions (Actionable Patient Safety Solutions™) and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005501/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
